Supercharge Your Innovation With Domain-Expert AI Agents!

Combination of anti-CD30 ADC, anti-PD-1 and chemotherapy to treat blood cancer

A PD-1, PD-L1 technology, applied in the direction of antibody medical components, antibodies, drug combinations, etc., can solve problems such as adjustment

Pending Publication Date: 2022-07-08
SEATTLE GENETICS INC
View PDF32 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

1 Despite regional variations, the most commonly used first-line regimen ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) has not been adjusted since its initial description in 1975

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of anti-CD30 ADC, anti-PD-1 and chemotherapy to treat blood cancer
  • Combination of anti-CD30 ADC, anti-PD-1 and chemotherapy to treat blood cancer
  • Combination of anti-CD30 ADC, anti-PD-1 and chemotherapy to treat blood cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0177] Described herein is an open-label, multicenter, phase 2 trial evaluating rentuximab vedotin, an anti-PD-1 antibody (nivolumab), doxorubicin, and dacarbazine (AN +AD) as first-line therapy in previously untreated patients with stage III / IV classical Hodgkin lymphoma (cHL).

[0178] The combination of Bentuximab vedotin and nivolumab appears to be active and well tolerated in cHL. In a trial of 62 subjects in the first rescue setting, the combination produced a 61% CR rate (Herrera et al., 2018 Blood 131(11):1183-94), and subjects were able to receive a subsequent stem cell transplant. In another trial of 19 subjects with relapsed / refractory cHL who had received a median of 3 prior treatments, the combination produced a CR rate of 50% (Diefenbach et al., 2017, Hematol Oncol 35(Suppl 2): ​​84-5). In another trial of 11 previously untreated cHL subjects over 60 years of age who were ineligible for reduced conventional combination chemotherapy, the combination of lentuxim...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates generally to methods of treating hematological cancers comprising administering an anti-CD30 antibody drug conjugate in combination with additional cancer therapeutic agents such as checkpoint inhibitors and chemotherapy regimens.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims the benefit of priority from U.S. Provisional Patent Application No. 62 / 905,701, filed September 25, 2019, the disclosure of which is incorporated herein by reference in its entirety. [0003] Incorporated by reference in electronically submitted materials [0004] The Sequence Listing, which is a part of this disclosure, is filed concurrently with the specification as a text document. The name of the text file containing the sequence listing is "54784_Seqlisting.txt", which was created on September 24, 2020 and is 7,899 bytes in size. The subject matter of the Sequence Listing is incorporated herein by reference in its entirety. technical field [0005] The present disclosure relates generally to the treatment of Hodgkin's lymphoma and other blood cancers with anti-CD30 antibody drug conjugate therapy in combination with an anti-PD-1 antibody and optionally with a chemotherapy regimen comprising...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00
CPCC07K16/2878C07K16/2818A61K2039/507C07K2317/21C07K2317/24C07K2317/76A61K2039/545A61K39/395C07K2317/73A61K2039/505A61K2300/00A61K47/6867A61K39/3955A61K31/704A61K31/4164A61P35/00A61K47/6849A61K31/655A61K38/193A61K39/39558A61K2039/54
Inventor 托马斯·曼利
Owner SEATTLE GENETICS INC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com